Dasatinib-induced colitis: clinical, endoscopic and histological findings.

Kenji Yamauchi, Tomoki Inaba, Hugh Shunsuke Colvin, Ichiro Sakakihara, Kumiko Yamamoto, Koichi Izumikawa, Sakuma Takahashi, Shigetomi Tanaka, Shigenao Ishikawa, Masaki Wato, Midori Ando, Masato Waki

Scandinavian journal of gastroenterology 2022 Apr

filter terms:

Dasatinib, a second-generation tyrosine kinase inhibitor, is widely used in patients with haematological malignancies. The main side effects of dasatinib are myelosuppression and pleural effusion; however, colitis, such as haemorrhagic colitis and cytomegalovirus (CMV) colitis, have been reported as rare side effects. There are only a few studies conducted on dasatinib-induced colitis. This study aimed to clarify the clinical, endoscopic and pathological features of dasatinib-induced colitis. This retrospective study included 51 consecutive patients who received dasatinib therapy between June 2009 and July 2020. Dasatinib-induced colitis was defined as the presence of colitis symptoms, exclusion of other diseases that could cause colitis, and improvement in symptoms after dasatinib withdrawal or dose reduction. CMV positivity was determined based on the positive result of CMV immunostaining. Dasatinib-induced colitis was diagnosed in nine of 51 patients (17.6%), and most of the symptoms were mild diarrhoea and bloody stools. The endoscopic findings were characterised by loss of vascular pattern (100%) and multiple small erosions (83.3%) which were mainly found in the transverse and descending colon. In a patient who underwent follow-up colonoscopy once a year while taking dasatinib, endoscopic findings changed from initial erythematous spots to multiple erosions, and finally to multiple small round elevations with erosion on the top that disappeared after discontinuation of dasatinib. Anti-CMV therapy was administered to one patient, but the treatment failed. All patients with dasatinib-induced colitis were cured after the discontinuation of dasatinib. Physicians should consider CMV reactivation to manage dasatinib-induced colitis.

Citation

Kenji Yamauchi, Tomoki Inaba, Hugh Shunsuke Colvin, Ichiro Sakakihara, Kumiko Yamamoto, Koichi Izumikawa, Sakuma Takahashi, Shigetomi Tanaka, Shigenao Ishikawa, Masaki Wato, Midori Ando, Masato Waki. Dasatinib-induced colitis: clinical, endoscopic and histological findings. Scandinavian journal of gastroenterology. 2022 Apr;57(4):449-456